Rubius Therapeutics, a Cambridge, MA-based biotechnology company pioneering the development of a new class of cell therapies, raised $120m in funding.
The company was conceived, launched and funded by Flagship VentureLabs, the innovation foundry of Flagship Pioneering, which was joined by undisclosed large institutional investors.
The proceeds will be used to accelerate the advancement of Rubius’ Red-Cell Therapeutics™ (RCT™) product portfolio, to further build out the team and to prepare to enter human clinical trials in 2018.
Led by Torben Straight Nissen, Ph.D., President, Noubar Afeyan, CEO of Flagship Pioneering and Co-Founder of the company, Rubius has developed the technology to grow, genetically engineer and mature long-circulating red cell therapeutics which will provide clinical benefits to a wide range of patients across multiple therapeutic areas.
The platform allows Rubius to express enzymes, agonists, antagonists, binders and combinations in their natural conformation on or inside of red cells. Lead RCT programs include enzyme replacement therapies as well as therapies targeting solid tumors and hematological cancers. Further, the company has demonstrated that RCTs provide potential applications across additional therapeutic areas, such as autoimmune disease, infectious disease, metabolic disease and rare diseases, including hemophilia.